| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/10/268:00 AM | -$0.32 | -$0.52GAAP | -62.5% | -30% | — | $0 | — | — | |
| Q2 '26 | 8/14/268:00 AM | -$0.40 | -$0.34GAAP | +15.0% | +17% | — | $0 | — | — | |
| Q1 '26 | 5/12/268:00 AM | -$0.39 | -$0.34GAAP | +12.8% | 0% | — | $0 | — | — | |
| Q4 '25 | 3/6/268:00 AM | -$0.40 | -$0.34GAAP | +15.0% | +24% | — | $0 | — | — | |
| Q3 '25 | 11/12/258:00 AM | -$0.40 | -$0.40GAAP | 0.0% | -8% | — | $0 | — | — | |
| Q2 '25 | 8/7/258:00 AM | -$0.39 | -$0.41GAAP | -5.1% | -1,950% | — | $0 | — | — | |
| Q1 '25 | 5/9/258:00 AM | -$0.38 | -$0.34GAAP | +10.5% | -13% | — | $0 | — | — |
GAAP = diluted EPS as filed with the SEC.